India's Cipla to buy Hetero Drugs' US business for about $550 mln

September 4, 2015 3:30 AM

20 0

MUMBAI, Sept 4 Indian generic drugmaker Cipla Ltd is set to buy the U.S. business of privately held rival Hetero Drugs for about $550 million, the Economic Times newspaper reported on Friday, citing people close to the transaction.

The newspaper said Cipla would buy U.S.-based Camber Pharmaceuticals and InvaGen Pharmaceuticals. (

Also read: Report: Galaxy S8 Plus Expected To Outsell Galaxy S8

Read more

To category page